rs111406936 - HABP2
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH - Unknown journal (n.d.) · Unknown authors · PubMed 37233759
ABSTRACT: Aims/hypothesis Characterisation of genetic variation that influences the response to glucose-lowering medications is instrumental to precision medicine for treatment of type 2 diabetes. The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) examined the acute response to metformin and glipizide in order to identify new pharmacogenetic associations for the response to common glucose-lowering medications in individuals at risk of type 2 diabetes. Methods One thousand participants at risk for type 2 diabetes from diverse ancestries underwent sequential glipizide and metformin challenges. A genome-wide association study was performed using the Illumina Multi-Ethnic Genotyping Array. Imputation was performed with the TOPMed referen
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
HABP2 T allele and metformin response Moderate
The T allele at rs111406936 is associated with higher insulin levels at 60 minutes after metformin administration, indicating altered drug response.
If considering metformin therapy, discuss this variant with your doctor to optimize dosing and monitoring.